Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| With the strong financial foundation and the right team in place, we believe Y-mAbs is positioned to continue improving outcomes for patients and families impacted by childhood cancers, while at the same time potentially shifting the treatment paradigm for a variety of both pediatric and adult cancers with our novel pretargeted radioimmunotherapy platform |
| Y-mAbs emerged as an innovator in radiopharmaceutical therapy development based on our novel and differentiated Pretargeted Radioimmunotherapy platform SADA PRIT, complemented by our commercial antibody therapy DANYELZA, driving annual revenue growth |
| But for some of these things like lutetium, there's a pretty good safety and track record on that already |
| While we continue to expect meaningful traction from the new campaign over the coming quarters, I am really pleased with the positive initial feedback in the form of commercial progress of DANYELZA in the US that we saw in just the fourth quarter |
| We continue to see an upward trend of sales growth since the initial launch back in 2021 and we believe we have room for continued growth |
| We are very encouraged by what we have seen so far |
| We finished 2023 on a strong note, achieving $23.4 million in net product sales of DANYELZA in the fourth quarter, an increase of 42% from what we recorded in the fourth quarter of 2022 and an increase of 17% versus the third quarter of 2023 |
| Through continued market penetration across high-volume US accounts and in ex-US regions, we are pleased to have achieved an annual 2023 net product revenue for DANYELZA of $84.3 million, which was near the top end of our previously raised guidance range of between $80 million and $85 million |
| As we look at these differentiators around infrastructure and manufacturing, administration and the ability to choose different isotopes in real-time as well as decrease toxicity levels to patient while increasing the targeted activity to tumors, we are very excited about the potential of SADA PRIT to improve patient experience and expand radiopharmaceutical treatment landscape |
| The progress is remarkable and indicates increasing adoption of DANYELZA across approved regions worldwide |
| Because we are leveraging the existing infrastructure, we are increasing physician participation and we are able to have more engagement with oncologists, specialists, and nuclear medicine physicians, which we believe will lead to better overall results |
| We're very encouraged by the early data we've seen so far and incredibly excited about the potential of SADA PRIT to emerge as the preferred radiopharmaceutical treatment platform of choice for physicians and their patients |
| We believe Y-mAbs is strongly positioned to execute on our strategic mission and our priorities and to support the delivery of multiple milestones |
| But we're very happy with how the safety trial is progressing |
| We hope to see a higher growth rate for DANYELZA as we execute our refined commercial strategy and work to deliver new clinical data that could potentially lead to expanded indications and greater decision adoption |
| We continue to gain momentum in the US with a number of new accounts |
| We truly believe that SADA PRIT novel and differentiated approach has the potential to become the targeted radiopharmaceutical delivery platform of choice in the treatment of multiple solid tumors and blood cancers |
| They've made all this progress possible and I'm very proud to work alongside team members who put patients at the forefront of all that they do day-in and day-out |
| Our global DANYELZA net product revenues of $23.4 million for the fourth quarter 2023 represented a 42% increase compared to the fourth quarter of 2022 and a favorable 17% increase compared to the third quarter of 2023, as we saw increases from US revenues as well as from international revenues |
| We are currently in Part A and are very pleased with how the trial is progressing |
| Our US commercial sales team continues to receive positive HCP feedback on DANYELZA through ongoing customer interactions |
| Competition is good and the ability to give patients and physicians choices on treatment |
| Us revenues increased 19% to $19.1 million in the fourth quarter compared to $16.1 million in the third quarter of 2023, and international revenues increased 11% to $4.3 million in the fourth quarter compared to $3.9 million in the third quarter |
| We have successfully rolled out a new DANYELZA campaign aimed to reposition and elaborate on DANYELZA's differentiating characteristics in the treatment of neuroblastoma for patients who have experienced incomplete response to induction therapy in their bone and bone marrow |
| The increase of $35 million was primarily driven by an increase in new us patients and an incremental benefit from expanding international revenues |
| Our goal at SADA PRIT is to solve all of these challenges and provide a simpler and more efficient solution for physicians that will have a greatly improved impact on patient care |
| But long term, it expands the opportunity of physicians to treat individual patients |
| We believe the potential of the radiopharmaceutical industry is at a huge inflection point and piquing the interests of physicians and patients alike |
| In addition, the new campaign demonstrates DANYELZA's response in children after prior anti-GD2 therapy |
| In addition to geographic expansion, we continue to see progress among our ongoing ISS-sponsored naxitamab trials in support of our indication expansion strategy |
| Statement |
|---|
| As manufacturers work to build the infrastructure I just referred to drug shortages have become a reality and patient care is delayed |
| So it's really challenging for some organizations to move forward |
| And fourth, continued drug shortages are an issue as current demand is increasing for radiopharmaceuticals |
| Second is physician participation which has always been an issue |
| Importantly, we reduced our annual cash used from $75.8 million to $27.1 million, about 64% in '23 compared to 2022 |
| In addition to our more focused pipeline, we reduced our cash -- use of cash to only $27.1 million in the full year 2023 as a direct result of our effective capital management strategy in action |
| One of the challenges that I spoke to is the ability to have flexibility in manufacturing |
| Before I provide a brief update on our lead programs, I want to take a moment to set the stage around some of the current challenges related to commercialization, administration, and manufacturing and infrastructure of targeted radiopharmaceutical therapies |
| Additionally, we reported a net loss for the year ended December 31st, 2023, of $21.4 million or $0.49 per share basic and diluted compared to a net loss of $95.6 million, or $2.19 per share basic and diluted for the year ended December 31st, 2022 |
| We reported net loss for the quarter ended December 31st, 2023 of just $1 million or $0.02 per share basic and diluted compared to net income of $1.2 million or $0.03 per share basic and diluted for the quarter ended December 31st, 2022, which included a regulatory based milestone of $15 million from SciClone Pharmaceuticals for the conditional approval of DANYELZA in China in 2022 |
| So, it's reduced about five basis points to eight basis points compared to what we saw in 2023 just to be conservative |
| The decrease was $27.1 million for the full year |
| Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's Annual Report on Form 10-K for the year ended December 31st, 2023, as filed with the SEC on February 29th, 2024 |
| Our research and development expenses decreased by $6.4 million and $37.4 million to $13.4 million and $54.2 million for the three months and year ended December 31st, 2023, respectively, compared to the same periods of 2022 |
| The net decrease was primarily due to the decreased spending on deprioritized programs in connection with our restructuring plan announced in January 2023, which resulted in decreases in outsourced manufacturing, outsourced research and supplies, clinical trials, and personnel-related costs |
Please consider a small donation if you think this website provides you with relevant information